Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
J Cancer Res Clin Oncol
; 136(3): 371-8, 2010 Mar.
Article
em En
| MEDLINE
| ID: mdl-19711099
ABSTRACT
INTRODUCTION:
This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC).METHODS:
The analysis included 292 patients 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w.RESULTS:
Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047).CONCLUSION:
Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ósseas
/
Carcinoma de Células Renais
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasias Renais
Tipo de estudo:
Evaluation_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Cancer Res Clin Oncol
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Polônia